Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G)

Vaccine

Volumn 23, Issue 44, 2005, Pages 5149-5159

  Maier, Marcel ^a   Seabrook, Timothy J ^a   Lemere, Cynthia A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Neurologic Diseases   (United States)

Author keywords

Adjuvant; Alzheimer's disease; Amyloid beta immunization

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIBODY; CHOLERA TOXIN B SUBUNIT; CORD FACTOR; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; M 6536; PHOSPHORYL LIPID A; PROTEIN ANTIBODY;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL PROLIFERATION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TITRIMETRY; VACCINATION; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; BACTERIAL TOXINS; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LIPID A; MALE; MICE;

EID: 25144520056     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.06.018     Document Type: Article

References (71)

1. G. Small, P. Rabins, P. Barry, N. Buckholtz, S. DeKosky, and S. Ferris Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society JAMA 278 1997 1363 1371
2. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 5580 2002 353 356
3. M. Citron Strategies for disease modification in Alzheimer's disease Nat Rev Neurosci 5 9 2004 677 685
4. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
5. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 8 2000 916 919
6. H.L. Weiner, C.A. Lemere, R. Maron, E.T. Spooner, T.J. Grenfell, and C. Mori Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease Ann Neurol 48 4 2000 567 579
7. E.M. Sigurdsson, H. Scholtzova, P.D. Mehta, B. Frangione, and T. Wisniewski Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice Am J Pathol 159 2 2001 439 447
8. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, and S.D. Schmidt A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 6815 2000 979 982
9. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, and J. Hardy A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 6815 2000 982 985
10. J.-C. Dodart, K. Bales, K. Gannon, S. Greene, R. DeMattos, and C. Mathis Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model Nat Neurosci 5 5 2002 452 457
11. D. Schenk Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning Nature 3 2002 824 828
12. E. Check Nerve inflammation halts trial for Alzheimer's drug Nature 415 6871 2002 462
13. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, and B. Muller-Tillmanns Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 4 2003 547 554
14. A.J. Bayer, R. Bullock, R.W. Jones, D. Wilkinson, K.R. Paterson, and L. Jenkins Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD Neurology 64 1 2005 94 101
15. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, and L.C. Kirby Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 1 2003 46 54
16. K. Birmingham, and S. Frantz Set back to Alzheimer vaccine studies Nat Med 8 3 2002 199 200
17. C.A. Lemere, R. Maron, D.J. Selkoe, and H.L. Weiner Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease DNA Cell Biol 20 11 2001 705 711
18. T.M. Doherty, A.W. Olsen, L. van Pinxteren, and P. Andersen Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis Infect Immun 70 6 2002 3111 3121
19. L. Vernacchio, H. Bernstein, S. Pelton, C. Allen, K. MacDonald, and J. Dunn Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers Vaccine 20 31-32 2002 3658 3667
20. J.R. Baldridge, Y. Yorgensen, J.R. Ward, and J.T. Ulrich Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration Vaccine 18 22 2000 2416 2425
21. T.C. VanCott, R.W. Kaminski, J.R. Mascola, V.S. Kalyanaraman, N.M. Wassef, and C.R. Alving HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160 J Immunol 160 4 1996 2000 2012
22. L.G. Durrant, and I. Spendlove Cancer vaccines entering Phase III clinical trials Expert Opin Emerg Drugs 8 2 2003 489 500
23. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, and A. Schuind Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 9447 2004 1757 1765
24. G. De Becker, V. Moulin, B. Pajak, C. Bruck, M. Francotte, and C. Thiriart The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells Int Immunol 12 6 2000 807 815
25. J.R. Baldridge, C.W. Cluff, J.T. Evans, M.J. Lacy, J.R. Stephens, and V.G. Brookshire Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529 J Endotoxin Res 8 6 2002 453 458
26. J. Ismaili, J. Rennesson, E. Aksoy, J. Vekemans, B. Vincart, and Z. Amraoui Monophosphoryl lipid A activates both human dendritic cells and T cells J Immunol 168 2 2002 926 932
27. J.R. Baldridge, and J.R. Ward Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity Vaccine 15 4 1997 395 401
28. R. Ryll, Y. Kumazawa, and I. Yano Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids - a review Microbiol Immunol 45 12 2001 801 811
29. K. Fujihashi, T. Koga, F. van Ginkel, Y. Hagiwara, and J. McGhee A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants Vaccine 20 2002 2431 2438
30. T.R. Hirst, T.O. Nashar, R.S. Pitman, and N.A. Williams Cholera toxin and related enterotoxins as potent immune modulators Symp Ser Soc Appl Microbiol 27 1998 26S 34S
31. B. de Geus, M. Dol-Bosman, J.W. Scholten, W. Stok, and A. Bianchi A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization Vaccine 15 10 1997 1110 1113
32. H.Y. Wu, and M.W. Russell Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant Vaccine 16 2-3 1998 286 292
33. C. Rask, M. Fredriksson, M. Lindblad, C. Czerkinsky, and J. Holmgren Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant Apmis 108 3 2000 178 186
34. J. Holmgren, A.M. Harandi, and C. Czerkinsky Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA Expert Rev Vaccines 2 2 2003 205 217
35. B.L. Dickinson, and J.D. Clements Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity Infect Immun 63 5 1995 1617 1623
36. C.A. Lemere, E.T. Spooner, J.F. Leverone, C. Mori, and J.D. Clements Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants Neurobiol Aging 23 6 2002 991 1000
37. T.J. Seabrook, J.K. Bloom, M. Iglesias, E.T. Spooner, D.M. Walsh, and C.A. Lemere Species-specific immune response to immunization with human versus rodent A beta peptide Neurobiol Aging 25 9 2004 1141 1151
38. T.J. Seabrook, M. Iglesias, J.K. Bloom, E.T. Spooner, and C.A. Lemere Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice Vaccine 22 29-30 2004 4075 4083
39. Y.I. Kawamura, R. Kawashima, Y. Shirai, R. Kato, T. Hamabata, and M. Yamamoto Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation Eur J Immunol 33 11 2003 3205 3212
40. C.O. Elson Cholera toxin and its subunits as potential oral adjuvants Curr Top Microbiol Immunol 146 1989 29 33
41. D.M. Walsh, A. Lomakin, G.B. Benedek, J.E. Maggio, M.M. Condron, and D.B. Teplow Amyloid b-protein fibrillogenesis: detection of a protofibrillar intermediate J Biol Chem 272 1997 22364 22374
42. M.M. Racke, L.I. Boone, D.L. Hepburn, M. Parsadainian, M.T. Bryan, and D.K. Ness Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta J Neurosci 25 3 2005 629 636
43. F.D. Finkelman, J. Holmes, I.M. Katona, J.F. Urban Jr., M.P. Beckmann, and L.S. Park Lymphokine control of in vivo immunoglobulin isotype selection Annu Rev Immunol 8 1990 303 333
44. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, and D. Games Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology Proc Natl Acad Sci USA 100 4 2003 2023 2028
45. T. Bussiere, F. Bard, R. Barbour, H. Grajeda, T. Guido, and K. Khan Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance Am J Pathol 165 3 2004 987 995
46. C. Dickey, D. Morgan, S. Kudchodkar, D. Weiner, Y. Bai, and C. Cao Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1-42 peptide DNA Cell Biol 20 11 2001 723 729
47. E.M. Sigurdsson, E. Knudsen, A. Asuni, C. Fitzer-Attas, D. Sage, and D. Quartermain An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives J Neurosci 24 28 2004 6277 6282
48. S. Oddo, L. Billings, J.P. Kesslak, D.H. Cribbs, and F.M. LaFerla Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome Neuron 43 3 2004 321 332
49. D.M. Wilcock, A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, and J. Alamed Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition J Neurosci 24 27 2004 6144 6151
50. R.B. Smeltz, and R.H. Swanborg Concordance and contradiction concerning cytokines and chemokines in experimental demyelinating disease J Neurosci Res 51 2 1998 147 153
51. R.H. Swanborg Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity Immunol Rev 184 2001 129 135
52. R. Aharoni, D. Teitelbaum, O. Leitner, A. Meshorer, M. Sela, and R. Arnon Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1 Proc Natl Acad Sci USA 97 21 2000 11472 11477
53. M.K. Shaw, J.B. Lorens, A. Dhawan, R. DalCanto, H.Y. Tse, and A.B. Tran Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis J Exp Med 185 9 1997 1711 1714
54. C.A. Lemere, E.T. Spooner, J. LaFrancois, B. Malester, C. Mori, and J.F. Leverone Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice Neurobiol Dis 14 1 2003 10 18
55. K.M. Neuzil, J.E. Johnson, Y.W. Tang, J.P. Prieels, M. Slaoui, and N. Gar Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine Vaccine 15 5 1997 525 532
56. T. Town, M. Vendrame, A. Patel, D. Poetter, A. DelleDonne, and T. Mori Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42) J Neuroimmunol 132 2002 49 59
57. P. Das, S. Chapoval, V. Howard, C.S. David, and T.E. Golde Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies Neurobiol Aging 24 7 2003 969 976
58. N.K. Childers, K.L. Miller, G. Tong, J.C. Llarena, T. Greenway, and J.T. Ulrich Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen Infect Immun 68 10 2000 5509 5516
59. D.H. Cribbs, A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, and N. Sadzikava Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid Int Immunol 15 4 2003 505 514
60. A. Monsonego, R. Maron, V. Zota, D.J. Selkoe, and H.L. Weiner Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease Proc Natl Acad Sci USA 98 18 2001 10273 10278
61. A.M. Harandi, J. Sanchez, K. Eriksson, and J. Holmgren Recent developments in mucosal immunomodulatory adjuvants Curr Opin Investig Drugs 4 2 2003 156 161
62. D.I. Albu, A. Jones-Trower, A.M. Woron, K. Stellrecht, C.C. Broder, and D.W. Metzger Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins J Virol 77 10 2003 5589 5597
63. K. Eriksson, M. Fredriksson, I. Nordstrom, and J. Holmgren Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development Infect Immun 71 4 2003 1740 1747
64. F.W. van Ginkel, R.J. Jackson, Y. Yuki, and J.R. McGhee Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues J Immunol 165 9 2000 4778 4782
65. R. Glueck Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization Vaccine 20 Suppl. 1 2001 S42 S44
66. M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, and T. Linder Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland N Engl J Med 350 9 2004 896 903
67. Y. Hagiwara, T. Iwasaki, H. Asanuma, Y. Sato, T. Sata, and C. Aizawa Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain Vaccine 19 13-14 2001 1652 1660
68. A. Eriksson, and N. Lycke The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability Vaccine 22 2 2003 185 193
69. A.M. Eriksson, K.M. Schon, and N.Y. Lycke The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues J Immunol 173 5 2004 3310 3319
70. T.J. Seabrook, J.K. Bloom, E.T. Spooner, and C.A. Lemere The use of Aβ1-15 multi-antigen peptide as a potential vaccine for Alzheimer's disease. Slide 830.1 Presented at the 34th Meeting of the Society for Neuroscience October 23-27, San Diego, CA 2004 [Abstract available online at http://sfn.scholarone.com ]
71. M. Maier, T.J. Seabrook, J.K. Bloom, and C.A. Lemere Alternative adjuvants and Aβ immunogens for Aβ immunotherapy. Slide 830.2 Presented at the 34th meeting of the Society for Neuroscience October 23-27, San Diego, CA 2004 [Abstract available online at http://sfn.scholarone.com ]